AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
AN2 Therapeutics, Inc. (ANTX)
US:NYSE Investor Relations:
ir.antheminc.com
Company Research
Source: Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025.The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all stockholders of the Company and ensure that the Board remains in the best position to discharge its fiduciary duties to the Company and its stockholders. The rights plan will guard against efforts to capitalize on the recent share price of the Company through
Show less
Read more
Impact Snapshot
Event Time:
ANTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANTX alerts
High impacting AN2 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ANTX
News
- AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and MalariaBusiness Wire
- Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
- AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan [Yahoo! Finance]Yahoo! Finance
ANTX
Earnings
- 8/13/24 - Beat
ANTX
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 3
- ANTX's page on the SEC website